BRAF and central nervous system cancer: The VE-BASKET trial assessed vemurafenib in various non-melanoma BRAF V600E mutant tumors, including gliomas, showing a 25% ORR with a median PFS of 5.5 months and a median OS of 28.2 months in the overall population [132].